Captor Therapeutics S.A. Logo

Captor Therapeutics S.A.

Develops Targeted Protein Degradation therapies for cancer and autoimmune diseases.

CTX | WAR

Overview

Corporate Details

ISIN(s):
PLCPTRT00014 (+1 more)
LEI:
259400JHH1S2I2S4O735
Country:
Poland
Address:
Wrocław Duńska 11, 54-427 Wrocław

Description

Captor Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapeutics for diseases with high unmet medical needs. The company specializes in Targeted Protein Degradation (TPD), a technology that enables the elimination of disease-causing proteins previously considered "undruggable." Its core research and development activities are centered on creating new treatments for cancer and autoimmune diseases. To achieve this, Captor Therapeutics utilizes its proprietary Optigrade™ platform. This integrated drug discovery engine combines advanced technologies, including structural biology, proteomics, molecular modeling, and protein engineering, to identify and optimize novel drug candidates. The platform is designed to accelerate the development of degraders with superior therapeutic properties, aiming to provide new treatment options for severe conditions.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2019-09-25 18:24
Sprawozdanie Zarządu z Działalności OAT
Polish 1.3 MB
2019-09-25 18:24
Jednostkowe Sprawozdanie Finansowe OAT
Polish 1.4 MB
2019-09-25 18:24
Skonsolidowane Sprawozdanie Finansowe OAT
Polish 1.4 MB
2019-09-19 14:54
Zmiana terminu publikacji raportu okresowego za pierwsze półrocze 2019 roku. - …
Polish 917 bytes
2019-08-07 11:31
Zawiadomienie w trybie art. 19 MAR
Polish 1.0 MB
2019-08-07 11:31
Informacja o transakcjach na akcjach Spółki otrzymana na podstawie art. 19 MAR …
Polish 564 bytes
2019-06-20 21:25
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Wa…
Polish 1.5 KB
2019-06-20 21:21
Treść uchwał podjętych podczas ZWZA
Polish 658.9 KB
2019-06-20 21:21
Treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie w dniu 19 czerwca 201…
Polish 1.1 KB
2019-06-05 12:14
Zawiadomienie w trybie art. 19 MAR
Polish 1.0 MB
2019-06-05 12:14
Informacja o transakcjach na akcjach Spółki otrzymana na podstawie art. 19 MAR …
Polish 420 bytes
2019-05-23 12:12
Projekty uchwał Zwyczajnego Walnego Zgromadzenia
Polish 395.5 KB
2019-05-23 12:12
Sprawozdanie Rady Nadzorczej
Polish 448.6 KB
2019-05-23 12:12
Projekty uchwał Zwyczajnego Walnego Zgromadzenia Akcjonariuszy - Content (PL)
Polish 669 bytes
2019-05-23 12:06
Ogłoszenie o zwołaniu Zwyczajnego Walnego Zgromadzenia
Polish 643.2 KB

Automate Your Workflow. Get a real-time feed of all Captor Therapeutics S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Captor Therapeutics S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Captor Therapeutics S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.